Digoxin pharmacokinetic parameters before and after supplementation/drug phases (mean ± S.D.)
Supplement/Drug Phase | AUC(0-3) | AUC(0-24) | CL/F | t1/2 | Cmax |
|---|---|---|---|---|---|
| ng/h/ml | ng/h/ml | l/h | h | ng/ml | |
| Pre-clarithromycin | 4.0 ± 0.9 | 14.1 ± 2.7 | 18.8 ± 6.7 | 32.1 ± 9.4 | 2.1 ± 0.5 |
| Post-clarithromycin | 7.3 ± 1.8a | 22.1 ± 4.5a | 8.4 ± 2.7a | 57.5 ± 20.4a | 4.1 ± 1.1a |
| Pre-rifampin | 4.8 ± 1.4 | 15.0 ± 4.1 | 19.0 ± 8.4 | 33.2 ± 12.8 | 2.5 ± 0.9 |
| Post-rifampin | 3.5 ± 1.1a | 12.6 ± 3.6a | 25.3 ± 12.9b | 27.9 ± 9.2b | 1.8 ± 0.5c |
| Pre-goldenseal | 4.1 ± 1.2 | 13.8 ± 3.4 | 22.1 ± 9.4 | 29.9 ± 12.0 | 2.1 ± 0.7 |
| Post-goldenseal | 4.5 ± 1.3 | 14.0 ± 3.5 | 20.7 ± 8.1 | 32.4 ± 13.0 | 2.4 ± 0.8b |
| Pre-kava kava | 4.0 ± 1.1 | 13.2 ± 2.6 | 22.6 ± 8.9 | 28.6 ± 8.6 | 2.2 ± 0.6 |
| Post-kava kava | 4.0 ± 1.2 | 13.4 ± 3.0 | 23.8 ± 8.9 | 28.6 ± 10.5 | 2.1 ± 0.7 |